Ulrich Rodeck, MD
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice
- Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound
- Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine
- Skinflammation and drug toxicity-A delicate balance
- Skin toxicity of targeted cancer agents: Mechanisms and intervention
Research and Clinical Interests
Regulation of epithelial cell fate by the epidermal growth factor receptor and associated signal transduction events; molecular mechanisms leading to adverse events of cancer therapy; adverse event reduction by developing drugs targeted to disease sites; zebrafish as an in vivo model system to investigate whole organism genotoxic stress responses.
My research interests revolve around signal transduction pathways regulating epithelial cell death and survival. Specifically, I am interested in coordinated signaling by receptor tyrosine kinases and integrins as it relates to the inappropriate survival of tumor cells. In these studies, we frequently use an EGFR antagonistic monoclonal antibody originally developed at the Wistar Institute (Rodeck et al. Cancer Res., 47:3692-6, 1987) and currently in phase II clinical trials in epithelial neoplasms (EMD59000; EMD72000). A second line of investigation focuses on molecular determinants of stress response pathways in vertebrate organisms. This work is done largely in zebrafish embryos to account or microenvironmental and tissue-specific effects. The goal of these studies is to identify targets for therapeutic intervention in cancer and inflammatory diseases.